You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
普華和順(01358.HK)輸液器業務中期收入預降35%至45%
格隆匯 07-06 17:55

格隆匯 7 月 6日丨普華和順(01358.HK)發佈公告,預期集團於截至2020年6月30日止六個月將錄得來自集團輸液器業務的收入較去年同期的人民幣1.723億元大幅下降35%至45%之間。

公告表示,,來自集團輸液器業務的收入預期下降主要由於2020年初開始爆發新型冠狀病毒疫情,中國若干地區的醫院人流量大幅減少以及中國實施旅行限制。集團已密切關注市場狀況,調整其業務策略及運營,以便降低負面影響。

此外,如公司此前披露,監於2020年5月完成出售泰邦生物集團公司部分股份的估計一次性收益,集團預期該一次性出售收益將對截至2020年6月30日止六個月公司擁有人應占溢利作出重大貢獻。

儘管存在上文所述情況,集團目前並不能合理估計經扣除該一次性出售收益後截至2020年6月30日止六個月的公司擁有人應占溢利,乃由於截至該公告日期公司尚未取得2020年第二季度對泰邦生物投資的業績表現。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account